Key result
Cangrelor therapy in a critically ill patient with an epidural catheter in situ requires careful management of neuraxial techniques and consideration of platelet function tests.
Why the study?
Comorbid conditions requiring anticoagulation can complicate the management of neuraxial catheters, including when critically ill patients require antiplatelet therapy with cangrelor.
Case Report (n=1)
Highlights the management challenges of using intravenous cangrelor in critically ill patients with an epidural catheter in situ.
Answers are grounded in this paper and cite their sources.
Requires individualized cangrelor timing with indwelling neuraxial catheters; case report leaves optimal protocols open.
Management of neuraxial catheters mandates consideration of comorbid conditions requiring anticoagulation, which may complicate their management. Cangrelor is an intravenous P2Y12 inhibitor with a plasma half-life of 3 to 6 minutes. Its use is indicated to reduce the risk of stent thrombosis. We present a case of a patient with an epidural catheter in situ who became critically ill, requiring antiplatelet therapy with cangrelor. We discuss pertinent considerations of neuraxial techniques in patients requiring cangrelor therapy and review existing guidelines for the management of these patients as well as current evidence of the use of platelet function tests in this setting.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) conducted a case report in Critically ill with epidural catheter requiring antiplatelet therapy (n=1). Cangrelor was evaluated. Cangrelor therapy in a critically ill patient with an epidural catheter in situ requires careful management of neuraxial techniques and consideration of platelet function tests.
Synapse has enriched 10 related papers. Consider them for comparative context: